Research & Development
NBE-Therapeutics will leverage its in-house developed Transpo-mAb and SMAC-Technology for the development of potent next-generation ADC product candidates providing improved treatment options for cancer patients.
- Basel, 2017-11-28 - NBE-Therapeutics appoints Dr. Nicole Onetto to its Board of Directors
- Lisbon, Portugal, 2017-11-14 - NBE-Therapeutics presented update on R&D activities at 2017-PEGS conference
- Basel, Switzerland, 2017-11-02 - NBE-Therapeutics presented update on R&D activities at 2017 HPAPI World Congress